Standard PCR-based mutation detection strategies performed on the *BRCA1*and *BRCA2*genes of breast and ovarian cancer families are mostly aimed at identifying changes in the coding sequences and in the donor-acceptor splice sites. Hence, mutations in the promoter and the untranslated regions, and large rearrangements, are not detected by these methods. To assess the importance of *BRCA1*and *BRCA2*alterations that are neglected by standard screening methods, we monitored germline rearrangements in these genes using \'multiplex ligation-dependent probe amplification\' technology \[[@B1]\]. One hundred and seventy-nine Norwegian breast and ovarian cancer families were screened for rearrangements in *BRCA1*while 97 families were tested for aberrations in *BRCA2*. Whereas no rearrangements were detected in *BRCA2*, four distinct deletions were found in *BRCA1*. Those deletions originating by Alu-mediated homologous recombination include: exons 1--13, exons 3--16, exons 8--13 and exon 23, respectively. The large 23.8 kb deletion excluding exons 8--13 in *BRCA1*has been found both in the French and British breast cancer population \[[@B2]-[@B4]\]. The deletions of exons 1--13, exons 3--16 and exon 23 have not been previously reported.
